{"id":37556,"date":"2025-07-18T14:27:32","date_gmt":"2025-07-18T06:27:32","guid":{"rendered":"https:\/\/flcube.com\/?p=37556"},"modified":"2025-07-18T14:27:32","modified_gmt":"2025-07-18T06:27:32","slug":"fosun-pharmas-zhejiang-xinghao-unit-initiates-phase-ib-study-for-copd-dpp-1-inhibitor-xh-s004","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37556","title":{"rendered":"Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004"},"content":{"rendered":"\n

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196<\/a>, HKG: 2196<\/a>) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset’s advancement to Phase II trials for non-cystic fibrosis bronchiectasis.<\/p>\n\n\n\n

XH-S004 Mechanism and Advantages<\/strong>
XH-S004 works by blocking DPP-1 and the downstream neutrophil serine proteases it activates, thereby reducing chronic airway inflammation and damage. Current COPD treatments primarily rely on bronchodilators and inhaled steroids, which have limited effects on neutrophilic inflammation. Only one type-2-targeted drug has been approved in China over the past two decades. XH-S004 offers a novel approach by potentially reducing exacerbations and slowing disease progression, with no DPP-1 mechanism yet approved globally.<\/p>\n\n\n\n

Clinical Development Progress<\/strong>
Fosun Pharma’s XH-S004 has shown promise in preclinical studies and earlier clinical trials. The initiation of the Phase Ib study in COPD represents a significant step forward in the development of this innovative therapy. The company aims to address the significant unmet medical needs in COPD management through this potential breakthrough treatment.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao…<\/p>\n","protected":false},"author":1,"featured_media":37557,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,159,893,892],"class_list":["post-37556","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"\nFosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset's advancement to Phase II trials for non-cystic fibrosis bronchiectasis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37556\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset's advancement to Phase II trials for non-cystic fibrosis bronchiectasis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37556\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-18T06:27:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004\",\"datePublished\":\"2025-07-18T06:27:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556\"},\"wordCount\":201,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37556#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37556\",\"name\":\"Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803.webp\",\"datePublished\":\"2025-07-18T06:27:32+00:00\",\"description\":\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset's advancement to Phase II trials for non-cystic fibrosis bronchiectasis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37556\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37556#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004 - Insight, China's Pharmaceutical Industry","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset's advancement to Phase II trials for non-cystic fibrosis bronchiectasis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37556","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004","og_description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset's advancement to Phase II trials for non-cystic fibrosis bronchiectasis.","og_url":"https:\/\/flcube.com\/?p=37556","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-18T06:27:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37556#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37556"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004","datePublished":"2025-07-18T06:27:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37556"},"wordCount":201,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37556#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803.webp","keywords":["Clinical trial approval \/ initiation","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37556#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37556","url":"https:\/\/flcube.com\/?p=37556","name":"Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37556#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37556#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803.webp","datePublished":"2025-07-18T06:27:32+00:00","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset's advancement to Phase II trials for non-cystic fibrosis bronchiectasis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37556#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37556"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37556#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803.webp","width":1080,"height":608,"caption":"Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37556#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37556"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37556\/revisions"}],"predecessor-version":[{"id":37558,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37556\/revisions\/37558"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37557"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}